INT16621

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1986
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 20
Total Number 20
Disease Relevance 8.20
Pain Relevance 4.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Esr1) nucleus (Esr1) enzyme binding (Esr1)
DNA binding (Esr1) protein complex (Esr1) transcription factor binding (Esr1)
Anatomy Link Frequency
uterine 3
brain 2
pituitary 2
neurons 1
MCF-7 1
Esr1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 40 100.00 Very High Very High Very High
dexamethasone 5 99.98 Very High Very High Very High
Spinal cord 11 99.92 Very High Very High Very High
Snapping jaw 94 99.68 Very High Very High Very High
Substantia gelatinosa neuron 1 99.54 Very High Very High Very High
Infliximab 4 97.68 Very High Very High Very High
metalloproteinase 7 97.56 Very High Very High Very High
Inflammation 35 97.36 Very High Very High Very High
spinal dorsal horn 6 97.32 Very High Very High Very High
Cholecystokinin 5 97.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Temporomandibular Joint Syndrome 92 99.68 Very High Very High Very High
Breast Cancer 98 99.60 Very High Very High Very High
Lordosis 2 98.08 Very High Very High Very High
INFLAMMATION 38 97.36 Very High Very High Very High
Weight Gain 8 97.08 Very High Very High Very High
Cv General 3 Under Development 17 96.88 Very High Very High Very High
Body Weight 6 96.88 Very High Very High Very High
Low Back Pain 9 96.56 Very High Very High Very High
Pain 15 95.32 Very High Very High Very High
Prolactinoma 84 93.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, T4 did prevent the normal estrogenic decrease of ER alpha mRNA levels in the nuclei of the limbic-hypothalamic circuit.
Negative_regulation (decrease) of ER alpha mRNA
1) Confidence 0.54 Published 1998 Journal Endocrinology Section Abstract Doc Link 9492057 Disease Relevance 0.06 Pain Relevance 0.30
Pretreatment with tamoxifen (TAM) 10 micromol/L, an inhibitor of estrogen receptor, did not block the effect of E2 on CBA.
Negative_regulation (inhibitor) of estrogen receptor
2) Confidence 0.47 Published 2001 Journal Acta Pharmacol. Sin. Section Body Doc Link 11743893 Disease Relevance 0 Pain Relevance 0
Knowing that on western blots estrogen receptor levels decreased in the TMJ region after injection of CFA, the question arose as to whether this decrease was due to a reduction in the number of cells expressing the receptor or to a decrease in the number of receptors per cell.
Negative_regulation (decreased) of estrogen receptor associated with snapping jaw
3) Confidence 0.47 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2811708 Disease Relevance 0.78 Pain Relevance 0.56
Down-regulation of estrogen receptor was suggested to involve some transcriptional activation mechanisms such as proteasome-mediated proteolysis activity [45,46].


Negative_regulation (Down-regulation) of estrogen receptor
4) Confidence 0.39 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2811708 Disease Relevance 0.30 Pain Relevance 0.25
These results suggest that the estrogen receptor is downregulated gradually after ovariectomy.
Negative_regulation (downregulated) of estrogen receptor
5) Confidence 0.38 Published 2004 Journal Bone Section Abstract Doc Link 15336606 Disease Relevance 0.36 Pain Relevance 0.34
Potentiation of excitatory transmission in substantia gelatinosa neurons of rat spinal cord by inhibition of estrogen receptor alpha

Background

Negative_regulation (inhibition) of estrogen receptor alpha in neurons associated with substantia gelatinosa neuron and spinal cord
6) Confidence 0.35 Published 2010 Journal Mol Pain Section Title Doc Link PMC3016347 Disease Relevance 0.26 Pain Relevance 0.39
The patients received adequate treatment with excellent results, exhibiting an increased weight, increased hemoglobin and decreased ESR.
Negative_regulation (decreased) of ESR
7) Confidence 0.25 Published 1991 Journal Rev Hosp Clin Fac Med Sao Paulo Section Abstract Doc Link 1843716 Disease Relevance 0.49 Pain Relevance 0.07
At the same time, uterine estrogen receptor affinity decreased.
Negative_regulation (decreased) of estrogen receptor in uterine
8) Confidence 0.25 Published 2004 Journal Horm. Metab. Res. Section Abstract Doc Link 14983405 Disease Relevance 0.18 Pain Relevance 0.27
Dexamethasone decreased estradiol-induced uterine cytosolic and nuclear estrogen receptor concentrations (E2 R0, p less than 0.05; E2nR0, respectively), but had no effect on estradiol-induced progesterone receptor concentrations (P4R0, p greater than 0.05).
Negative_regulation (decreased) of estrogen receptor in uterine associated with dexamethasone
9) Confidence 0.17 Published 1990 Journal Biol. Reprod. Section Abstract Doc Link 2310819 Disease Relevance 0.51 Pain Relevance 0.29
Experiment 2: Within which brain regions does an estrogen receptor antagonist block SKF 38393-induced Fos expression?
Negative_regulation (block) of estrogen receptor in brain associated with antagonist
10) Confidence 0.12 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2359852 Disease Relevance 0.25 Pain Relevance 0.27
Experiment 2: Within which brain regions does an estrogen receptor antagonist block SKF 38393-induced Fos expression?
Negative_regulation (block) of estrogen receptor in brain associated with antagonist
11) Confidence 0.12 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2359852 Disease Relevance 0.08 Pain Relevance 0.46
1) did not significantly reduce the electron spin resonance (ESR) signal intensity of hydroxyl radical (OH•) formation.
Neg (not) Negative_regulation (reduce) of ESR
12) Confidence 0.08 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Abstract Doc Link PMC2975073 Disease Relevance 0.71 Pain Relevance 0.19
Similar to the situation in humans, the regression of uterine ectopic implants could be induced in rats by generating a hypoestrogenic state, for example, by the application of GnRH agonists,14 by synthetic progestational compounds such as levonorgestrel or dienogest15,16 or by danazol treatment.17 Similar effects could be achieved in this model by reducing the estrogen concentration by the application of anti-estrogens, by using the selective estrogen receptor modulator raloxifen,18 by treatment with aromatase inhibitors that interfere with estrogen synthesis, or by ovariectomy.14
Negative_regulation (using) of estrogen receptor in uterine associated with agonist
13) Confidence 0.08 Published 2008 Journal Clinics Section Body Doc Link PMC2664131 Disease Relevance 0.28 Pain Relevance 0.15
If an endocrine disruptor or its metabolites bind, but do not activate the estrogen receptor, the substance acts as an antagonist and inactivates the estrogen receptor, preventing estradiol to bind.
Negative_regulation (inactivates) of estrogen receptor associated with antagonist
14) Confidence 0.07 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1524969 Disease Relevance 0 Pain Relevance 0.05
When the MORE and CORE trials were both considered (i.e. analyzing all 8 years of raloxifene therapy) the overall reduction in breast cancer incidence was 66%, with a 76% reduction in estrogen receptor-positive breast cancer.
Negative_regulation (reduction) of estrogen receptor associated with breast cancer
15) Confidence 0.07 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 0.94 Pain Relevance 0.09
In vitro, the parent compound and metabolite show strong inhibition of the estrogen receptor-positive MCF-7 breast cancer cell line, including those demonstrating tamoxifen resistance (Freddie et al. 2004).
Negative_regulation (inhibition) of estrogen receptor in MCF-7 associated with breast cancer
16) Confidence 0.06 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 0.47 Pain Relevance 0.03
Evaluating the results of all groups, we observed that pituitary PTTG was increased only if estrogen action was increased, which correlated with a decrease in pituitary estrogen receptor level.
Negative_regulation (decrease) of estrogen receptor in pituitary
17) Confidence 0.04 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1779802 Disease Relevance 0.86 Pain Relevance 0.04
Therefore, pituitary PTTG was increased only if estrogen action was increased, which correlated with a decrease in pituitary estrogen receptor level.


Negative_regulation (decrease) of estrogen receptor in pituitary
18) Confidence 0.04 Published 2007 Journal Mol Cancer Section Abstract Doc Link PMC1779802 Disease Relevance 0.91 Pain Relevance 0.14
Before each infusion and at week 10, the following were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, serum levels of metalloproteinase-3 (MMP-3), and 22 different cytokines.
Negative_regulation (measured) of ESR in platelet associated with metalloproteinase and cytokine
19) Confidence 0.04 Published 2008 Journal Clin. Rheumatol. Section Abstract Doc Link 18566849 Disease Relevance 0.25 Pain Relevance 0.55
No relationship was demonstrated between the protease inhibitor, alpha 2M and clinical activity, ESR or any of the APP.
Negative_regulation (inhibitor) of ESR
20) Confidence 0.02 Published 1986 Journal Br. J. Rheumatol. Section Abstract Doc Link 2423177 Disease Relevance 0.51 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox